

MANNKIND CORP
Form 8-K
October 05, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 5, 2012

MannKind Corporation

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction

of incorporation or organization)

000-50865
(Commission

File Number)

13-3607736
(IRS Employer

Identification No.)

Edgar Filing: MANNKIND CORP - Form 8-K

28903 North Avenue Paine Valencia,

California

(Address of principal executive offices)

Registrant's telephone number, including area code: (661) 775-5300

91355

(Zip Code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On October 5, 2012, MannKind Corporation announced that it had completed recruiting patients for two Phase 3 clinical studies of AFREZZA® (insulin human [rDNA origin]), an investigational, ultra rapid-acting mealtime insulin therapy, administered using MannKind's to-be-marketed next-generation inhaler. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release of MannKind Corporation dated October 5, 2012 announcing MannKind's Completion of Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MANNKIND CORPORATION

By: /s/ David Thomson

Name: David Thomson, Ph.D., J.D.

Title: Corporate Vice President, General
Counsel and Secretary

Dated: October 5, 2012

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release of MannKind Corporation dated October 5, 2012 announcing MannKind's Completion of Patient Recruitment in Two Phase 3 Clinical Studies of AFREZZA.